The Global Antipsychotic Drugs Market to Register Growth at a CAGR of ~7% by 2027 | DelveInsight
Retrieved on:
Giovedì, Febbraio 2, 2023
Pharmacy, Personality disorder, Pfizer, PTSD, Schizoaffective disorder, Safety, Sun Pharma, Lundbeck, Ethics, Cariprazine, Statistics, Anxiety, Alvogen, Bristol Myers Squibb, HDEC, Mental disorder, Bipolar I disorder, Disorder, Depression, Post-traumatic stress disorder, Food, Hallucination, DSM-IV codes, Zydus Lifesciences, Prevalence, USFDA, US Foods, LAS, Mental health, GSK, Laboratory, Government, MDMA, Thought, Addiction, USP, Schizophrenia, Sale, Bipolar disorder, Research, Agonist, Silvio Pettirossi International Airport, COVID-19, Bayer, GSK plc, Cardinal Health, World Health Organization, Drug development, Mania, WHO, Viatris, Conduct disorder, AbbVie, Delusion, Pharmaceutical industry, Medsafe
LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.
Key Points:
- LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.
- As per DelveInsight estimates, North America is anticipated to dominate the global antipsychotic drugs market during the forecast period.
- Furthermore, increased awareness resulted in increased adoption of these drugs in key countries, significantly increasing antipsychotic drugs market growth in key countries.
- However, the high cost of drug development and launch, addiction caused by antipsychotic drugs, and the stringent regulatory approval process may stall the antipsychotic drugs market growth.